TABLE I.
Monoclonal antibody (MAb) costs per patient per indication
| Schema component | Trastuzumab Breast | Bevacizumab | ||
|---|---|---|---|---|
| Adjuvant | Palliative | nsclc Palliative | Colorectal Palliative | |
| Dose a (mg/kg) | 8 (1st dose)→65,6 | 8 (1st dose)→6b,3,14 | 157 | 54 |
| Schedule a (every n weeks) | 35,6 | 33,14 | 37 | 24 |
| Duration a (months) | 125,6 | 7.23,14,15 | 6.47 | 10.64 |
| Total use c (mg) | 7700 | 4340 | 9450 | 7700 |
| Cost per milligram d ($CA) | 6.14 | 6.14 | 5.00 | 5.00 |
| MAb cost e ($CA) | 47,279 | 26,648 | 47,251 | 38,501 |
| MRU ($CA) | 2,637 | 1,702 | 1,239 | 1,113 |
| Total costs ($CA) | 49,916 | 28,350 | 48,490 | 39,614 |
a
Derived from the relevant clinical trials (see Table II).
b
Dose schedule as per local practice.
c
Calculated based on the dose, schedule, and duration of therapy.
d
Drug acquisition costs were based on 2005 average Canadian wholesale prices.
e
Calculated based on total use in milligrams multiplied by cost per milligram.
nsclc = non-small-cell lung cancer; $CA = 2005 Canadian dollars; mru = medical resource utilization.